Impact of age and comorbidity in Myelodysplastic syndromes

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 9, 2008, Pages 927-934

  Stauder, Reinhard ^a   Nösslinger, Thomas ^b   Pfeilstöcker, Michael ^b   Sperr, Wolfgang R ^c   Wimazal, Friedrich ^c   Krieger, Otto ^d   Valent, Peter ^c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b HANUSCH HOSPITAL   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d ELISABETHINEN HOSPITAL   (Austria)

Author keywords

Age; Comorbidity; Elderly; MDS; Myelodysplastic syndrome; Myeloid; Old

Indexed keywords

ANTILEUKEMIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; AGING; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CANCER RISK; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COMORBIDITY; CYTOGENETICS; DEPRESSION; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE SEVERITY; ELDERLY CARE; FUNCTIONAL DISEASE; GALLBLADDER DISEASE; GENETIC RISK; HEART FAILURE; HEART INFARCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; LIVER DISEASE; MALIGNANT TRANSFORMATION; MORTALITY; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; PRACTICE GUIDELINE; PROGNOSIS; RATING SCALE; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SOCIAL SUPPORT; SURVIVAL RATE; SURVIVAL TIME; WORLD HEALTH ORGANIZATION;

EID: 56049107314     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0070     Document Type: Article

References (49)

1. Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med 2005;56:1-16.
2. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007;31:727-736.
3. Greenberg P Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
4. Germing U, Hildebrandt B, Pfeilstöcker M, et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005;19:2223-2231.
5. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-7603.
6. Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006;91:1588-1590.
7. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25:3503-3510.
8. Carreca I, Balducci L, Extermann M. Cancer in die older person. Cancer Treat Rev 2005;31:380-402.
9. Aul C, Gattermann N, Heyll A, et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992;6:52-59.
10. Rocco G, Oberaigner W, Gastl G, et al. Myelodysplastic syndrome and acute myeloid leukemia in Tyrol: incidence and distribution [abstract]. Onkologie 2003;23(Suppl 5):S121. Abstract P683.
11. Germing U, Strupp C, Kundgen A, et al. No increase in age-specific incidence of myelodysplastic syndromes. Haernatologica 2004;89:905-910.
12. Pfeilstöcker M, Katlic H, Nösslinger T, et al. Myelodysplastic syndromes, aging, and age: correlations, cornmon mechanisms, and clinical implications. Leuk Lymphoma 2007;48:1900-1909.
13. Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 1998;83:358-368.
14. Sanz GF, Sanz MA, Villespi T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989;74:395-408.
15. Morel P, Hebbar M, Lai JL, et al. Cytogenetic analysis has strong prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993;7:1315-1323.
16. Noesslinger T, Tuechler H, Germing U, et al. Individualizing IPSS risk assessment in myelodysplastic syndromes, by additionally taking into account age, gender and French-American-British (FAB) classification - a multicenter analysis [abstract]. Blood 2006,107:Abstract 2618.
17. Kuendgen A, Strupp C, Aivado M, et al. Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol 2006;24:5358-5365.
18. Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring system in myelodysplastic syndromes. Haematologica 1998;83:358-368.
19. Balducci L, Baskin R, Cohen HJ, et al. NCCN Clinical Practice Guidelines in Oncology: Senior Adult Oncology. Version 2, 2007. Available at: http://www.nccn.org/professionals/physician_gls/PDF/senior.pdf. Accessed February 25, 2008.
20. Morel P, Declercq C, Hebbar M, et al. Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques. Br J Haematol 1996;94:116-119.
21. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis 1970;23:455-468.
22. Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of mate and female colon carcinoma patients: a population-based study. Cancer 1998;82:2123-2134.
23. Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006;295:801-808.
24. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-110.
25. Mitnitski AB, Song X, Rockwood K. The estimation of relative fitness and frailty in community-dwelling older adults using self-report data. J Gerontol A Biol Sci Med Sci 2004;59:M627-632.
26. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000;36:453-471.
27. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 2000;35:181-200.
28. Yates JW. Comorbidity considerations in geriatric oncology research. CA Cancer J Clin 2001;51:329-336.
29. Rao AV, Seo PH, Cohen HJ. Geriatric assessment and comorbidity. Semin Oncol 2004;31:149-159.
30. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 2003;56:221-229.
31. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
32. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-1251.
33. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968;16:622-626.
34. Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992;41:237-248.
35. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998;16:1582-1587.
36. Kaplan MH, Feinstein AR. The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 1974;27:387-404.
37. Greenfield S, Blanco DM, Elashoff RM, Ganz PA. Patterns of care related to age of breast cancer patients. JAMA 1987;257:2766-2770.
38. Balducci L. Aging, frailty, and chemotherapy. Cancer Control 2007;14:7-12.
39. Deschler B, de Witte T, Mertelsmann R, Lubbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006;91:1513-1522.
40. Pelz D, Nachtkamp K, Kündgen A, et al. Influence of comorbidity factors on the prognosis of patients with myelodysplastic syndromes (MDS). Leuk Res 2007;31(Suppl 1):S30-31.
41. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004;104:961-968.
42. Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004;104:1550-1558.
43. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912-2919.
44. Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007;25: 4246-4254.
45. Giles FJ, Borthakur G, Ravandi F, et al. The hematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukemia. Br J Haematol 2007;136:624-627.
46. Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006;144:407-414.
47. Artz AS, Pollyea DA, Kocherginsky M, et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006;12:954-964.
48. Della Porta MG, Malcovati, L Travaglino E, et al. A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes. Blood 2007;110:Abstract 2453.
49. Stauder R, Wimazal F, Nösslinger T, et al. Individualized management and therapy of myelodysplastic syndromes. Wiener Klinische Wochenschrift 2008; in press.